{"id":10996,"date":"2020-10-06T09:58:53","date_gmt":"2020-10-06T13:58:53","guid":{"rendered":"http:\/\/www.drugpatentwatch.com\/blog\/?p=10996"},"modified":"2026-04-14T22:58:47","modified_gmt":"2026-04-15T02:58:47","slug":"freedom-of-information-act-access-to-an-investigational-new-drug-application","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/freedom-of-information-act-access-to-an-investigational-new-drug-application\/","title":{"rendered":"How to FOIA an IND Application: The Complete Pharma Intelligence Playbook"},"content":{"rendered":"\n

For IP teams, portfolio managers, competitive intelligence leads, and institutional investors who need to know what the FDA is holding \u2014 and how to get it.<\/em><\/p>\n\n\n\n

What an IND Actually Contains \u2014 and Why It Matters to Competitors<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

An Investigational New Drug application is the document through which a sponsor formally requests FDA authorization to administer an unapproved drug or biological product to human subjects. Under 21 U.S.C. \u00a7 355(i) and the Hatch-Waxman framework, no sponsor may ship an unapproved investigational drug across state lines for clinical testing without an active IND on file with the FDA. The IND is, in effect, the statutory exemption mechanism that unlocks that prohibition.<\/p>\n\n\n\n

For competitive intelligence and IP strategy purposes, what the IND contains is the more consequential question. A complete IND submission includes the following categories of data:<\/p>\n\n\n\n

The preclinical pharmacology and toxicology section covers in vitro receptor binding, ADME (absorption, distribution, metabolism, excretion) characterization, genotoxicity assays, and species-specific toxicokinetics from GLP-compliant animal studies. This section typically identifies the no-observed-adverse-effect level (NOAEL) used to calculate the first-in-human dose via body-surface-area scaling \u2014 data that biosimilar developers and generic entrants would find extraordinarily useful in planning their own development programs.<\/p>\n\n\n\n

The chemistry, manufacturing, and controls (CMC) section documents the drug substance’s structural formula, synthesis route or fermentation\/upstream bioprocessing methodology, formulation composition, container-closure specifications, and release testing criteria. For small molecules, this is the manufacturing trade secret in its most granular form. For biologics, the CMC section contains cell line origin, bioreactor parameters, purification train design (e.g., Protein A capture, low-pH viral inactivation, tangential flow filtration), and glycosylation profile targets \u2014 all of which are the core of a reference biologic’s IP moat.<\/p>\n\n\n\n

The clinical protocols section includes the Phase 1 dose-escalation schema, pharmacokinetic sampling schedules, patient selection criteria, and primary endpoints. For sponsors racing to establish clinical proof-of-concept, this section reveals the exact scientific hypothesis being tested and the statistical power calculations underlying it.<\/p>\n\n\n\n

Annual IND reports and IND safety reports (also called 15-day expedited safety reports) are submitted continuously as the program matures, creating a longitudinal dataset on the compound’s emerging safety profile that no public source replicates.<\/p>\n\n\n\n

The reason this data sits at the center of competitive intelligence is straightforward: a competitor who can reconstruct even a partial picture of a rival’s CMC platform or Phase 1 design can make better in-licensing, out-licensing, and portfolio resource allocation decisions. The IND is the most detailed single document a sponsor ever files with the government about an investigational asset \u2014 and it is filed years before any NDA or BLA review makes any of it public.<\/p>\n\n\n\n

Key Takeaways: IND Contents<\/strong><\/h3>\n\n\n\n

The IND is not a summary. It is a technical dossier containing raw synthesis routes, GLP toxicology, manufacturing controls, and clinical protocols that represent years of R&D spend. Preclinical toxicology and CMC data are the sections of highest competitive sensitivity. Annual reports and safety reports filed against an active IND create a real-time window into program progress that no external observer normally has access to.<\/p>\n\n\n\n

\n\n\n\n

The Regulatory Architecture: FOIA, Exemption 4, and 21 CFR \u00a7 312.130<\/strong><\/h2>\n\n\n\n

FOIA’s Baseline Disclosure Mandate<\/strong><\/h3>\n\n\n\n

The Freedom of Information Act (5 U.S.C. \u00a7 552) establishes that any person \u2014 citizen or not, individual or corporation \u2014 may request records from any federal agency. The FDA, as a component of the Department of Health and Human Services, is fully subject to FOIA. The statute’s presumption is disclosure: agencies must release records unless a specific exemption applies.<\/p>\n\n\n\n

Nine exemptions exist. For pharmaceutical regulatory records, two dominate the analysis. Exemption 6 protects personal privacy in personnel and medical files. Exemption 4 \u2014 which protects ‘trade secrets and commercial or financial information obtained from a person that is privileged or confidential’ \u2014 is the primary shield the FDA deploys against IND disclosure requests.<\/p>\n\n\n\n

Exemption 4: The Trade Secrets Fortress<\/strong><\/h3>\n\n\n\n

The legal interpretation of Exemption 4 has shifted materially since the D.C. Circuit’s 2019 decision in Food Marketing Institute v. Argus Leader Media, in which the Supreme Court rejected the long-standing National Parks test (which required a showing of competitive harm) and held that ‘confidential’ under Exemption 4 means information that the provider customarily keeps private or shares only under an obligation of confidentiality. For pharmaceutical companies, this standard is easier to satisfy than its predecessor. Drug sponsors can now argue that IND data is ‘confidential’ simply by demonstrating that they do not voluntarily share such data externally \u2014 no specific competitive harm showing is required.<\/p>\n\n\n\n

That said, the FDA has historically applied an even broader interpretation. The agency has maintained that even confirming an IND exists \u2014 before any human trial has been publicly announced \u2014 can constitute disclosable information that harms the sponsor’s competitive position. This ‘no acknowledgment’ posture predates Argus Leader and is codified directly in regulation.<\/p>\n\n\n\n

21 CFR \u00a7 312.130: The Governing Regulation<\/strong><\/h3>\n\n\n\n

Title 21, Section 312.130 of the Code of Federal Regulations governs IND disclosure explicitly. Its operative provisions establish three core rules:<\/p>\n\n\n\n

The FDA will not disclose the existence of an IND unless that existence has already been publicly disclosed or officially acknowledged. This means that if a sponsor has filed an IND quietly \u2014 with no press release, no ClinicalTrials.gov registration, no SEC disclosure \u2014 the FDA will neither confirm nor deny its existence in response to a FOIA request.<\/p>\n\n\n\n

The availability of data within an IND follows different paths depending on the product type. For small molecule new drugs, disclosure follows 21 CFR \u00a7 314.430 (the NDA confidentiality regulation). For biological products, disclosure follows 21 CFR \u00a7\u00a7 601.50 and 601.51 (the BLA confidentiality regulations). This cross-referencing structure means IND data is treated with the same confidentiality as the eventual marketing application data, which is extensive.<\/p>\n\n\n\n

Two carve-outs require mandatory disclosure regardless of commercial sensitivity: IND safety reports must be disclosed upon request to any individual who received the investigational drug under that IND, and information from INDs that received the 21 CFR \u00a7 50.24 exception from informed consent (emergency research) is accessible through a specific FOIA pathway via the FDA’s Dockets Management Staff, referencing Docket Number 95S-0158 (formerly 95S-1061).<\/p>\n\n\n\n

21 CFR \u00a7 314.430: The NDA Confidentiality Cross-Reference<\/strong><\/h3>\n\n\n\n

Under \u00a7 314.430, if an NDA has not been approved and its existence has not been publicly disclosed, no data or information within it is available for public disclosure. Once an NDA is approved, certain safety and effectiveness data, summaries, and approval correspondence become available \u2014 but the pre-approval IND data that fed into the NDA remains subject to ongoing Exemption 4 analysis. The regulation creates a tiered timeline: confidentiality at submission, partial opening at approval.<\/p>\n\n\n\n

Key Takeaways: Regulatory Architecture<\/strong><\/h3>\n\n\n\n

The Argus Leader decision strengthened drug sponsors’ ability to claim Exemption 4 without demonstrating specific competitive harm. 21 CFR \u00a7 312.130’s ‘no acknowledgment’ rule means the FDA can refuse to confirm an IND exists, making blind FOIA requests nearly impossible to prosecute. The two mandatory disclosure carve-outs \u2014 individual safety reports and exception-from-informed-consent data \u2014 are narrow but real, and are worth pursuing in appropriate clinical contexts.<\/p>\n\n\n\n

\n\n\n\n

IND Data as a Core IP Asset: Valuation Implications<\/strong><\/h2>\n\n\n\n

The IND Portfolio as a Valuation Input<\/strong><\/h3>\n\n\n\n

For any pre-NDA pharmaceutical or biotech asset, the IND represents the most comprehensive technical disclosure ever made to a regulatory body \u2014 and by extension, one of the most concentrated repositories of IP-protective know-how a company holds. In standard pharma IP valuation frameworks (income approach via risk-adjusted NPV, cost approach via R&D spend replacement, or market approach via comparable transaction multiples), IND data quality directly influences multiple key variables.<\/p>\n\n\n\n

The rNPV of a pipeline asset is a function of the probability of technical success (PTS) at each clinical stage, the projected peak revenue, and the applicable discount rate. The toxicological and pharmacological data in a Phase 1 IND update PTS estimates \u2014 typically moving the Phase 1-to-Phase 2 transition probability from an industry-average baseline of roughly 52% (per Citeline\/Pharmaprojects data) to a more asset-specific figure informed by NOAEL values, safety margins, and first-in-human tolerability signals. A FOIA requester who obtains a competitor’s abandoned IND safety data can, in principle, recalibrate their own PTS modeling for a similar mechanism of action.<\/p>\n\n\n\n

The CMC sections of an IND carry an additional valuation dimension for biologics. A biologic’s manufacturing process is inseparable from its product quality \u2014 in regulatory terms, ‘the process is the product.’ The upstream parameters documented in an IND (cell line, bioreactor scale, process analytical technology specifications) establish the technical baseline against which biosimilar developers must demonstrate analytical similarity under the 351(k) pathway. For a reference biologic sponsor, protecting this CMC data from FOIA disclosure is not merely about maintaining competitive secrecy; it is about preserving the practical barriers to biosimilar entry that arise when competitors cannot reverse-engineer the manufacturing envelope.<\/p>\n\n\n\n

Cost Approach: What IND Data Replacement Would Cost<\/strong><\/h3>\n\n\n\n

Using a cost-to-replicate approach, the data packages within a full Phase 2 IND typically represent $25 million to $75 million in cumulative R&D expenditure (covering GLP toxicology, CMC development, Phase 1 conduct, and regulatory affairs costs). For biologics, CMC development costs alone for a monoclonal antibody can exceed $50 million prior to Phase 2 initiation. The FOIA protection of this data is, in a very direct sense, protection of a measurable asset value on the balance sheet.<\/p>\n\n\n\n

For abandoned INDs, this cost-basis argument cuts both ways. When a drug sponsor terminates a program, the sunk R&D cost does not disappear from the asset ledger \u2014 it converts into a write-down. But for a third-party researcher or competitor seeking FOIA access, the same data may carry significant positive optionality: the preclinical toxicology package for a failed oncology compound may be directly applicable to a new indication, and the Phase 1 PK data may support a new IND for a related molecule without the cost of repeat animal studies.<\/p>\n\n\n\n

Market Approach: Transaction Comps and IND Disclosure<\/strong><\/h3>\n\n\n\n

In M&A due diligence for pharma assets, the IND file room is standard deliverable. A buyer’s diligence team expects full access to all IND submissions, annual reports, clinical holds, and correspondence with the FDA. When a target company’s IND data has been previously disclosed via FOIA (even partially), the due diligence dynamic changes: a competitor may have already accessed data that the acquirer thought was proprietary. IP teams engaged in M&A should document the FOIA request history for any IND in the acquisition target’s portfolio.<\/p>\n\n\n\n

Key Takeaways: IP Valuation<\/strong><\/h3>\n\n\n\n

The IND data package represents a discrete, quantifiable IP asset \u2014 typically $25M-$75M in replacement cost for a Phase 2 program. FOIA disclosure of this data can impair competitive barriers, recalibrate competitor PTS models, and complicate M&A due diligence. For biologics, CMC data in an IND is practically synonymous with the manufacturing trade secret, and its protection has direct biosimilar market-exclusivity implications.<\/p>\n\n\n\n

Investment Strategy Note<\/strong><\/h3>\n\n\n\n

Portfolio managers evaluating pre-revenue biotech positions should track whether a target company’s INDs have been subject to FOIA requests \u2014 particularly from known competitors. FDA FOIA logs, available through the agency’s online reading room, can reveal whether requests have been filed against programs in a company’s portfolio. A pattern of competitor FOIA activity around a specific program is a soft signal of competitive pressure, useful alongside standard patent citation analysis and clinical trial registry monitoring.<\/p>\n\n\n\n

\n\n\n\n

The Confidentiality Ladder: Active vs. Abandoned vs. Post-Approval INDs<\/strong><\/h2>\n\n\n\n

Active INDs: Maximum Protection<\/strong><\/h3>\n\n\n\n

The FDA’s default position on an active, unapproved IND is complete confidentiality. The agency will not confirm the IND’s existence, will not release any data, and will invoke \u00a7 312.130 alongside Exemption 4 as dual grounds for denial. Even if the sponsor has registered a clinical trial on ClinicalTrials.gov \u2014 which provides the protocol title, indication, phase, enrollment criteria, and primary endpoints \u2014 the underlying IND data (preclinical toxicology, CMC, safety reports) remains withheld.<\/p>\n\n\n\n

The only active-IND pathway to disclosure is the mandatory safety report carve-out: if an individual participated in a clinical trial under that IND and requests their own safety-related data, the FDA must disclose the IND safety reports pertaining specifically to that person’s exposure. This is a patient-rights mechanism, not a competitive intelligence tool, and it is operationally limited to individuals with documented participation in the relevant trial.<\/p>\n\n\n\n

Inactive and Clinical Hold INDs: A Gray Zone<\/strong><\/h3>\n\n\n\n

An IND transitions to inactive status if no human subjects have been enrolled for two or more consecutive years, or if the FDA has imposed a clinical hold lasting at least one year. Inactive status does not automatically convert the IND to public record, but it weakens the sponsor’s Exemption 4 claim. A FOIA requester can reasonably argue that data within a multi-year-inactive IND has diminishing commercial sensitivity, particularly if the sponsor has not filed an NDA or made any public statement about the program in years.<\/p>\n\n\n\n

Clinical holds are separately instructive from an intelligence standpoint. Under 21 CFR \u00a7 312.42, the FDA may place an IND on clinical hold if it concludes that the proposed investigation poses unreasonable risk to subjects. Clinical hold letters themselves \u2014 distinct from the IND data they reference \u2014 may be accessible under FOIA, particularly when they relate to broad safety classes rather than proprietary compound-specific information. Obtaining a clinical hold letter for a competitor’s program can reveal the nature of the safety concern the FDA identified, informing a rival program’s development strategy.<\/p>\n\n\n\n

Abandoned INDs: The Primary Intelligence Opportunity<\/strong><\/h3>\n\n\n\n

When a sponsor formally withdraws an IND or when the FDA administratively terminates one following prolonged inactivity, the commercial sensitivity calculus shifts most dramatically. The sponsor no longer has an active commercial interest in the compound, and the FDA’s primary rationale for Exemption 4 protection \u2014 preventing harm to ongoing competitive activities \u2014 becomes harder to sustain.<\/p>\n\n\n\n

The Ro 24-7429 case (detailed below) is the clearest documented example of successful FOIA access to an abandoned IND. The key legal argument that succeeded was the combination of abandonment status and the specific framing of the request around safety and effectiveness data rather than manufacturing processes. The distinction matters: even in an abandoned IND, the CMC synthesis route or bioprocessing parameters may retain commercial value if the sponsor is still active in the therapeutic area or if the manufacturing technology is platform-applicable.<\/p>\n\n\n\n

Post-Approval INDs: The Retrospective Window<\/strong><\/h3>\n\n\n\n

After an NDA or BLA is approved, the IND that supported the application does not become public in its entirety. What becomes available is the approval package: the approval letter, the approved labeling, the FDA’s final clinical, pharmacology, and statistical reviews, and \u2014 for applications processed before approximately 2000 \u2014 the Summary Basis of Approval (SBA). The SBA is a consolidated safety-and-effectiveness narrative that often traces findings back through the Phase 1 and Phase 2 IND data, providing retrospective insight into what the preclinical and early clinical data showed.<\/p>\n\n\n\n

For applications approved after roughly 2000, the SBA was replaced by the full suite of FDA reviewer documents published via the Drugs@FDA portal. These documents \u2014 clinical pharmacology reviews, integrated summaries of safety, chemistry reviews \u2014 contain substantial IND-era data presented through the lens of the approval reviewers. A skilled analyst reading a modern NDA chemistry review can reconstruct significant elements of the IND CMC narrative without ever filing a FOIA request.<\/p>\n\n\n\n

Key Takeaways: Confidentiality Ladder<\/strong><\/h3>\n\n\n\n

Active INDs are essentially inaccessible. Inactive INDs occupy a legally contested middle ground where request framing matters enormously. Abandoned INDs are the primary FOIA target, and success correlates with specificity of request and focus on safety\/efficacy data over manufacturing trade secrets. Post-approval reviewer documents on Drugs@FDA replicate much of the IND-era data narrative without any FOIA effort required.<\/p>\n\n\n\n

\n\n\n\n

Case Studies: Ro 24-7429, Labetalol IND 18113, and What They Reveal<\/strong><\/h2>\n\n\n\n

Ro 24-7429 (Hoffman-La Roche): The Benchmark for Successful IND FOIA Access<\/strong><\/h3>\n\n\n\n

Ro 24-7429 was an HIV integrase strand-transfer inhibitor (INSTI) candidate developed by Hoffmann-La Roche in the early 1990s, prior to the company’s pivot toward other antiretroviral mechanisms. The compound was eventually abandoned after early clinical data showed insufficient antiviral activity at tolerated doses.<\/p>\n\n\n\n

Researchers studying integrase inhibition as a class subsequently filed a FOIA request with the FDA specifically targeting Ro 24-7429’s IND. The FDA’s response was unusually productive: the agency provided the IND application number and disclosed 464 pages of material, including the FDA’s own pharmacology review (the internal document in which agency scientists evaluated Roche’s submitted preclinical data) and an annual IND report that contained the investigational drug brochure, clinical study protocols, and protocol amendments.<\/p>\n\n\n\n

The researchers’ success rested on several factors. They argued that Roche had publicly abandoned the program and had no ongoing commercial interest in the data. They focused their request specifically on safety and effectiveness data rather than CMC or manufacturing specifics. They framed the request around scientific utility \u2014 specifically, the value of the data for understanding integrase biology and informing new INSTI development \u2014 rather than competitive purposes.<\/p>\n\n\n\n

Even so, the researchers themselves noted that their experience was atypical. The FDA’s decision to release these materials was not the product of a clear regulatory rule mandating release; it reflected a fact-specific judgment call. Other researchers requesting comparable data from other abandoned INDs have not necessarily replicated this outcome. The case illustrates that FOIA access to IND data is genuinely possible under the right conditions, but it is not predictable enough to serve as a reliable intelligence pipeline.<\/p>\n\n\n\n

From an IP valuation standpoint, the Ro 24-7429 disclosure is instructive. The pharmacology review obtained by researchers effectively documented the FDA’s scientific assessment of the compound’s mechanism, dose-response, and toxicity profile \u2014 data that Roche had spent millions of dollars generating. Once disclosed, that data became a public good that any subsequent INSTI developer could use to inform their own preclinical design. This is precisely the competitive harm the FDA’s confidentiality posture is designed to prevent in active programs.<\/p>\n\n\n\n

Labetalol IND 18113 (Schering): Litigation as the Only Path<\/strong><\/h3>\n\n\n\n

The Public Citizen Health Research Group’s attempt to access information from Schering’s IND 18113 for labetalol (a combined alpha\/beta-adrenergic blocker) took a different trajectory. Unlike the Ro 24-7429 case, where the FDA released data with relative cooperation, Schering’s IND required an initial FOIA request, a subsequent lawsuit in federal district court, and an appeal before any data was released \u2014 and even then, the result was only a partial judgment in favor of disclosure.<\/p>\n\n\n\n

The labetalol case pre-dates the Argus Leader decision, and it was litigated under the older National Parks competitive harm standard for Exemption 4. Schering argued that the IND data constituted confidential commercial information whose disclosure would harm its competitive position. Public Citizen argued that the public health interest in understanding labetalol’s safety profile outweighed Schering’s commercial interest in confidentiality.<\/p>\n\n\n\n

The court’s partial ruling \u2014 not a complete release but a selective disclosure \u2014 reflects the judicial reluctance to force wholesale IND disclosure. Courts have historically deferred to the FDA’s case-by-case disclosure judgments rather than imposing categorical rules. For practitioners considering FOIA litigation for IND data, the labetalol case establishes the baseline expectation: even a favorable judgment may yield incomplete disclosure, and the litigation timeline can span years.<\/p>\n\n\n\n

The cost-benefit calculus for IND FOIA litigation is significant. Federal FOIA litigation requires filing in U.S. district court, typically in the D.C. Circuit, and involves agency document review, Vaughn index preparation, and potentially in-camera judicial review of withheld documents. For a biotech IP team or an academic research group, the legal costs can easily reach $100,000-$500,000 before any documents are produced. The expected value calculation therefore requires a clear assessment of what the specific IND data is worth if obtained.<\/p>\n\n\n\n

Key Takeaways: Case Studies<\/strong><\/h3>\n\n\n\n

Ro 24-7429 remains the clearest precedent for successful voluntary IND disclosure, but it depended on program abandonment, specific data framing, and a cooperative FDA determination. The labetalol case illustrates that litigation yields partial results at best and is expensive to pursue. Both cases predate or occurred contemporaneously with Argus Leader, which has since strengthened sponsor confidentiality arguments under Exemption 4.<\/p>\n\n\n\n

Investment Strategy Note<\/strong><\/h3>\n\n\n\n

For competitive intelligence teams, these cases establish the practical playbook: target abandoned programs in therapeutic areas adjacent to active internal programs, frame requests around safety\/efficacy data rather than manufacturing, and build a public interest narrative that does not reference competitive purpose. For legal teams advising pharma sponsors, both cases reinforce the value of proactive IND withdrawal documentation that records the sponsor’s commercial abandonment clearly \u2014 which, paradoxically, may make eventual FOIA disclosure more likely but also removes the asset from active valuation, creating a clean trade-off.<\/p>\n\n\n\n

\n\n\n\n

How to Submit a High-Probability FOIA Request for IND Data<\/strong><\/h2>\n\n\n\n

Pre-Request Intelligence Gathering<\/strong><\/h3>\n\n\n\n

Before filing any FOIA request with the FDA, conduct a systematic pre-request search to determine what is already publicly available. ClinicalTrials.gov (clinicaltrials.gov) is the mandatory registration database for trials of FDA-regulated products. Trials initiated after December 2007 are required to be registered, and results must be posted within 12 months of primary completion date under the Final Rule implementing FDAAA 801. A ClinicalTrials.gov record reveals the IND protocol design, dose ranges, endpoints, study sites, enrollment figures, and \u2014 in results records \u2014 primary and safety outcome data. This is often a sufficient substitute for the IND protocol sections.<\/p>\n\n\n\n

The Drugs@FDA database (accessdata.fda.gov\/scripts\/cder\/daf\/) contains the full approval packages for all approved NDAs and BLAs, including FDA reviewer documents that retrospectively analyze IND-era data. For any approved compound, these documents should be reviewed before filing a FOIA request.<\/p>\n\n\n\n

The FDA’s FOIA Electronic Reading Room (fda.gov\/regulatory-information\/freedom-information\/foia-electronic-reading-room) contains previously released documents. If another requester has already obtained data from the IND you are targeting, that data may already be publicly available without any additional filing.<\/p>\n\n\n\n

PubMed, bioRxiv, and the clinical pharmacology literature often contain peer-reviewed publications from IND-sponsored Phase 1 trials. Regulatory agencies also publish Briefing Documents for Advisory Committee meetings that contain substantial IND-era data for the drugs under review.<\/p>\n\n\n\n

Drafting the Request: Specificity Over Breadth<\/strong><\/h3>\n\n\n\n

FOIA requests for IND data fail most often because of breadth and vagueness. The FDA receives more than 15,000 FOIA requests per year across all program areas. Requests that ask for ‘all information’ about a compound generate maximum fee exposure and minimum probability of substantive disclosure.<\/p>\n\n\n\n

A high-probability IND FOIA request includes the following elements:<\/p>\n\n\n\n

Identify the drug by INN (International Nonproprietary Name) or sponsor trade name, the IND application number if publicly known (sometimes disclosed in clinical trial registry entries or sponsor press releases), and the specific time period of interest. If the IND number is not known, request the IND number itself as the first item, followed by the specific documents.<\/p>\n\n\n\n

Specify the document categories being requested. For abandoned INDs targeting safety data, request the FDA’s pharmacology review documents, IND safety reports (15-day and annual), and the investigational drug brochure. Do not request CMC sections or synthesis\/manufacturing data in an initial request \u2014 these are the most likely to be withheld under Exemption 4, and including them gives the FDA a broader surface area to deny in full.<\/p>\n\n\n\n

Include an explicit public interest fee waiver argument if applicable. FOIA’s fee waiver standard requires that the disclosure ‘is in the public interest because it is likely to contribute significantly to public understanding of the operations or activities of the government’ and ‘is not primarily in the commercial interest of the requester.’ Academic institutions and public health research organizations have a significantly easier path to fee waivers than pharmaceutical companies or their counsel.<\/p>\n\n\n\n

Indicate a maximum fee cap. Request that the FDA contact you before incurring any costs above $100 (for routine requests) or state a specific maximum. This prevents surprise invoices and gives the agency a checkpoint to confirm the scope is workable.<\/p>\n\n\n\n

Submission Mechanics<\/strong><\/h3>\n\n\n\n

The FDA’s preferred submission method is electronic, through the online FOIA request portal at accessdata.fda.gov\/scripts\/foi\/FOIRequest. Mail submissions go to the Division of Headquarters Freedom of Information, FDA, Room 12A-30, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Fax submissions are not currently accepted. Requests submitted through FOIA.gov are routed to the appropriate agency but may add processing time.<\/p>\n\n\n\n

Address the request to the Center for Drug Evaluation and Research (CDER) FOIA Office for small molecule drugs, or to the Center for Biologics Evaluation and Research (CBER) FOIA Office for vaccines, blood products, and biological therapeutics. Misdirected requests get re-routed internally but lose days in processing.<\/p>\n\n\n\n

Key Takeaways: FOIA Request Strategy<\/strong><\/h3>\n\n\n\n

The single highest-return step before filing is exhausting public databases \u2014 ClinicalTrials.gov results records, Drugs@FDA, and the FOIA Electronic Reading Room often contain what researchers are seeking without any formal request. When filing, specificity is inversely correlated with denial risk. Requesting FDA pharmacology reviews and safety reports from an abandoned IND is a more viable strategy than requesting the full CMC package. Public interest fee waiver arguments should be drafted by counsel with FOIA litigation experience.<\/p>\n\n\n\n

\n\n\n\n

FDA Response Timelines, Staffing Gaps, and DOGE-Era Processing Delays<\/strong><\/h2>\n\n\n\n

Statutory Timelines vs. Operational Reality<\/strong><\/h3>\n\n\n\n

FOIA’s statutory timeline requires a federal agency to make a determination within 20 working days of receiving a request. The FDA may extend this by 10 working days for unusual circumstances (large volume, referral to another agency component, need for consultation). In practice, neither deadline is consistently met.<\/p>\n\n\n\n

As of 2024, the FDA’s backlog of open FOIA requests numbered in the thousands. Average response times for complex requests \u2014 the category most IND-related requests fall into \u2014 have at times exceeded 200 working days, or roughly 9-10 calendar months. A 2023 analysis published by Logikcull found that the FDA’s FOIA processing times were among the longest of any major federal agency, driven by the technical complexity of pharmaceutical regulatory records, the volume of Exemption 4 review required, and chronic understaffing in the Office of Information Management and Technology (OIMT), which handles FOIA processing for CDER and CBER.<\/p>\n\n\n\n

2025 DOGE Staffing Reductions and Their FOIA Impact<\/strong><\/h3>\n\n\n\n

The Department of Government Efficiency (DOGE)-driven workforce reductions at HHS and FDA in early 2025 created a new processing bottleneck. As the FDA Law Blog reported in April 2025, FDA staff reductions in the records management and regulatory information functions directly affected FOIA processing capacity. The FDA’s FOIA office relies on program staff to conduct the substantive technical review needed to determine what can be released from a complex pharmaceutical record. When program reviewers are reduced \u2014 as occurred across multiple CDER divisions in the 2025 RIF (Reduction In Force) \u2014 FOIA processing slows proportionally, because the technical expertise needed to conduct redaction review disappears with the staff.<\/p>\n\n\n\n

For practitioners filing IND-related FOIA requests in 2025 and 2026, the practical implication is that response times are longer than historical averages would suggest, and appeals of constructive denials (where the agency simply fails to respond within the statutory deadline) may be necessary sooner than in prior years. FOIA regulations permit a requester to treat the agency’s failure to respond within 20 working days as a constructive denial, triggering the right to appeal or sue without waiting for an official denial letter.<\/p>\n\n\n\n

Tracking Your Request<\/strong><\/h3>\n\n\n\n

The FDA’s FOIA tracking system allows requesters to monitor their case status at accessdata.fda.gov\/scripts\/foi\/foirequest. Case numbers are assigned upon submission. Requests that have been pending for more than 30 working days without substantive response warrant a written follow-up to the FOIA office identifying the case number, original submission date, and a request for a projected response date. Phone follow-ups are generally less productive than written inquiries, which create a documented record.<\/p>\n\n\n\n

Key Takeaways: Response Timelines<\/strong><\/h3>\n\n\n\n

Plan for 6-12 months of processing time for any IND-related FOIA request, not 20 working days. DOGE-era staffing reductions have made 2025-2026 processing times materially longer than historical baselines. Build in a constructive denial appeal strategy at the 20-working-day mark, and document all follow-up communications for potential litigation use.<\/p>\n\n\n\n

\n\n\n\n

When to Appeal and When to Litigate<\/strong><\/h2>\n\n\n\n

The Administrative Appeal<\/strong><\/h3>\n\n\n\n

A FOIA requester who receives a full or partial denial from the FDA has the right to file an administrative appeal with the FDA’s Office of the Chief Counsel (OCC) within 90 days of the denial. The appeal must identify the specific documents denied, the exemption claimed by the FDA, and the requester’s argument for why the exemption does not apply. For IND-related denials under Exemption 4, post-Argus Leader appeals typically argue either that the information was not ‘customarily kept private’ (because the sponsor has disclosed similar data in other contexts, e.g., regulatory submissions in the EU or clinical trial results publications) or that the information at issue is factual rather than proprietary (e.g., basic pharmacology data that parallels published scientific literature).<\/p>\n\n\n\n

The administrative appeal record is important for subsequent litigation. Courts reviewing FOIA denials under de novo review will examine the agency’s Vaughn index \u2014 a document-by-document description of each withheld item and the exemption claimed \u2014 and may conduct in-camera review. A well-developed administrative appeal that precisely identifies the deficiencies in the FDA’s Exemption 4 analysis creates a stronger record for judicial challenge.<\/p>\n\n\n\n

Federal District Court Litigation<\/strong><\/h3>\n\n\n\n

FOIA lawsuits are filed in U.S. district court. Venue is proper in the D.C. District (where the FDA’s headquarters is located), in the district where the requester resides or has their principal place of business, or in the district where the records are located. The D.C. District is the most common venue for pharmaceutical FOIA litigation because D.C. Circuit precedents on Exemption 4 are the most developed.<\/p>\n\n\n\n

Litigation proceeds on cross-motions for summary judgment based on the agency’s Vaughn index and any supporting declarations. If the court finds the Vaughn index insufficient, it can order in-camera review of the withheld documents or additional agency declarations. Courts are not required to defer to the agency’s Exemption 4 determinations \u2014 review is de novo \u2014 but in practice, judges with limited pharmaceutical regulatory expertise often credit detailed agency declarations.<\/p>\n\n\n\n

The labetalol litigation timeline illustrates the resource commitment: the case required years of administrative and judicial process to produce partial disclosure. For most pharmaceutical companies pursuing IND data for competitive intelligence, the cost-benefit analysis does not support FOIA litigation. The exception is when the specific data sought has a quantifiable value that exceeds litigation costs \u2014 for example, a biosimilar developer attempting to access reference biologic manufacturing data that would reduce a multi-million-dollar CMC development program.<\/p>\n\n\n\n

Key Takeaways: Appeals and Litigation<\/strong><\/h3>\n\n\n\n

File the administrative appeal within 90 days of any denial. Use the appeal to build the factual record for potential litigation. Litigation is economically rational only when the specific data has a value clearly exceeding litigation costs, and when the Exemption 4 argument is factually weak (e.g., the information sought has been publicly disclosed in analogous form by the sponsor in another jurisdiction). The D.C. District is the preferred venue.<\/p>\n\n\n\n

\n\n\n\n

Post-NDA and Post-BLA Disclosure: The Retrospective Intelligence Window<\/strong><\/h2>\n\n\n\n

What Drugs@FDA Provides Without Any FOIA Request<\/strong><\/h3>\n\n\n\n

For any drug or biologic that has received FDA approval, the Drugs@FDA database is the first and most productive intelligence resource. The approval package for a standard NDA typically includes the medical officer review, the pharmacology\/toxicology review, the statistical review, the clinical pharmacology review, the chemistry review (which covers the drug substance and drug product manufacturing), the microbiology review (for anti-infectives), and the labeling review.<\/p>\n\n\n\n

Each of these reviewer documents represents an FDA scientist’s detailed technical analysis of the sponsor’s submitted data. The clinical pharmacology review, for example, will present the PK\/PD model the FDA used to evaluate the IND’s proposed dosing \u2014 a model built directly from IND Phase 1 pharmacokinetic data. The pharmacology\/toxicology review will summarize the preclinical safety findings from the IND toxicology studies, often including the specific NOAEL values and the species-specific toxicokinetic parameters. The chemistry review will discuss the manufacturing process at a level sufficient to evaluate it for approval purposes, including process controls, specifications, and stability data.<\/p>\n\n\n\n

For a competitor analyst, these documents provide substantial reconstruction of what the IND contained without requiring any FOIA filing. The primary limitation is that FDA reviewer documents present the agency’s synthesis of the sponsor’s data rather than the raw data itself \u2014 they describe the study outcomes but may not reproduce the individual patient-level datasets or the full analytical method validation packages.<\/p>\n\n\n\n

The Summary Basis of Approval (SBA) and Its Modern Equivalents<\/strong><\/h3>\n\n\n\n

For applications approved before approximately 2000, the FDA prepared a Summary Basis of Approval that consolidated the key safety and effectiveness findings into a single narrative document. SBAs are publicly available through FOIA and, for older approvals, are often already in the FOIA Electronic Reading Room. They are particularly useful for drugs that completed development during a period when ClinicalTrials.gov did not yet exist as a disclosure mechanism.<\/p>\n\n\n\n

For applications approved after 2000, the equivalent intelligence comes from the full suite of reviewer documents in the Drugs@FDA approval package, the Risk Evaluation and Mitigation Strategy (REMS) documentation (where applicable), and the Prescribing Information (labeling), which must include the clinical studies section with key efficacy and safety data from the pivotal trials.<\/p>\n\n\n\n

European Medicines Agency (EMA) Transparency Policy<\/strong><\/h3>\n\n\n\n

Analysts targeting global pharmaceutical assets should be aware that the EMA’s clinical data publication policy (Policy 0070, effective 2016) provides substantially broader access to clinical study reports than the FDA FOIA regime. Under Policy 0070, the EMA publishes redacted clinical study reports submitted as part of a centralized marketing authorization application (MAA), covering Phase 2 and Phase 3 clinical trial data. These clinical study reports \u2014 often thousands of pages in length \u2014 contain individual patient data summaries, statistical analysis plans, and protocol deviations that go well beyond what FDA reviewer documents provide. For compounds approved in both the U.S. and EU, the EMA clinical study reports represent the most efficient pathway to IND-era clinical data without FDA FOIA barriers.<\/p>\n\n\n\n

Key Takeaways: Post-Approval Disclosure<\/strong><\/h3>\n\n\n\n

Drugs@FDA approval packages provide detailed retrospective reconstruction of IND-era data for approved compounds without any FOIA filing. For pre-2000 approvals, seek the Summary Basis of Approval directly. For EU-approved compounds, EMA’s Policy 0070 clinical study reports provide the deepest clinical data disclosure available anywhere in the regulatory system. Use these resources to scope what is already public before designing any FOIA strategy.<\/p>\n\n\n\n

\n\n\n\n

FOIA and Biologics: BLA-Specific Confidentiality Under 21 CFR \u00a7\u00a7 601.50 and 601.51<\/strong><\/h2>\n\n\n\n

The BLA Confidentiality Framework<\/strong><\/h3>\n\n\n\n

For biological products regulated by CBER and CDER (including monoclonal antibodies, recombinant proteins, gene therapies, and cell therapies), IND disclosure follows 21 CFR \u00a7\u00a7 601.50 and 601.51 rather than \u00a7 314.430. The substantive confidentiality rules are similar \u2014 the FDA will not disclose BLA-related information before approval \u2014 but the regulatory context differs in ways that matter for biosimilar competition analysis.<\/p>\n\n\n\n

Under the Biologics Price Competition and Innovation Act (BPCIA), a biosimilar applicant filing under 351(k) must provide the reference product sponsor (RPS) with a copy of its 351(k) application and manufacturing information within 20 days of the FDA accepting the application for review. This initiates the ‘patent dance’ \u2014 the structured IP exchange process in which the RPS identifies patents it believes the biosimilar may infringe and the parties negotiate or litigate before the biosimilar’s approval. The patent dance involves disclosure of biosimilar manufacturing data to the RPS that is far more detailed than anything accessible through FOIA. But FOIA requests targeting the reference biologic’s BLA-era IND data remain blocked under \u00a7\u00a7 601.50 and 601.51 during the biologic’s regulatory exclusivity period.<\/p>\n\n\n\n

12-Year Biological Exclusivity and IND Data Protection<\/strong><\/h3>\n\n\n\n

Under the BPCIA, a reference biologic receives 12 years of regulatory exclusivity from the date of first approval (with a four-year data exclusivity period prohibiting FDA from accepting a 351(k) application for the first four years). During this 12-year window, the FDA will not approve a biosimilar regardless of the patent situation. This means that for a newly approved biologic, the sponsor’s IND data \u2014 including the manufacturing platform data documented in the original IND \u2014 is protected from FOIA-accessible disclosure through both the \u00a7 601.50\/601.51 confidentiality regulations and the practical irrelevance of the data to any near-term approval timeline.<\/p>\n\n\n\n

After the 12-year exclusivity period expires, the regulatory confidentiality rationale weakens in the same way it weakens for abandoned small-molecule INDs, but the commercial sensitivity of CMC data often persists because the manufacturing platform remains in active commercial use. A biosimilar developer seeking FOIA access to originator biologic IND manufacturing data 15 years after approval is unlikely to succeed because the FDA would likely still find Exemption 4 applicable to trade secret manufacturing information.<\/p>\n\n\n\n

The Gene Therapy and Cell Therapy IND Frontier<\/strong><\/h3>\n\n\n\n

INDs for gene therapies (viral vector-mediated gene delivery, in vivo editing via CRISPR delivery systems, ex vivo cell modification) and cell therapies (CAR-T constructs, allogeneic T cell products) represent the highest-complexity and highest-value IND data currently on file with CBER. These programs involve manufacturing processes \u2014 viral vector production, transduction efficiency protocols, cryopreservation chains \u2014 that are novel, platform-critical, and represent years of process development investment.<\/p>\n\n\n\n

For gene and cell therapy programs specifically, even the scale-up pathway from Phase 1 to commercial manufacturing is proprietary in a way that small-molecule synthesis rarely is. A Phase 1 IND for a lentiviral CAR-T product contains the vector genome design (which is directly covered by patent claims), the transduction parameters, the T cell activation and expansion protocol, and the release testing specification for the final drug product. Each of these elements is simultaneously a trade secret and potentially a patent claim. The FOIA barrier to this data is effectively absolute for active programs and remains high for abandoned programs because the manufacturing platform typically has application across multiple programs in the sponsor’s pipeline.<\/p>\n\n\n\n

Key Takeaways: Biologics and BLA Confidentiality<\/strong><\/h3>\n\n\n\n

The 12-year BPCIA exclusivity period effectively aligns with BLA\/IND confidentiality protections for biologics, creating a 12-year enforcement window during which FOIA access to originator BLA-linked IND data is practically impossible. Gene therapy and cell therapy INDs contain the highest-value IND data in the current regulatory environment and carry the strongest Exemption 4 protection. EMA Policy 0070 remains the most productive access route for clinical data from approved biologics, even where FDA FOIA fails.<\/p>\n\n\n\n

\n\n\n\n

Investment Strategy: Using FOIA Intelligence in Competitive Pharma Analysis<\/strong><\/h2>\n\n\n\n

The Intelligence Hierarchy for Pre-Revenue Pharma Assets<\/strong><\/h3>\n\n\n\n

Institutional investors and portfolio managers evaluating pre-NDA pharma and biotech assets work within a defined information hierarchy. At the top are SEC filings (10-K, 10-Q, 8-K) and conference presentations, which provide executive-curated narratives. Below that are ClinicalTrials.gov registrations and results records, peer-reviewed publications, conference abstracts, and investor day data packages. FOIA-derived IND data, when accessible, sits below all of these in terms of certainty of access \u2014 but above all of them in terms of raw data density and technical specificity.<\/p>\n\n\n\n

For a Phase 2-stage biotech with a single pipeline asset, the FDA’s internal pharmacology review of the original IND (if accessible via FOIA from an abandoned predecessor program in the same mechanism class) can provide a degree of technical due diligence that no public source replicates. It reveals what the FDA’s own scientists thought about the preclinical safety data \u2014 not what the company’s IR materials say about it.<\/p>\n\n\n\n

Competitive Intelligence Use Cases<\/strong><\/h3>\n\n\n\n

Several practical competitive intelligence applications emerge from the FOIA-IND framework.<\/p>\n\n\n\n

Mechanism-class analysis: If a company has filed an IND for a compound in a mechanism class where a predecessor compound’s IND was abandoned and is accessible via FOIA, the abandoned IND’s pharmacology review may reveal FDA-identified class effects (toxicity signals, PK liabilities) that inform the risk profile of the active program.<\/p>\n\n\n\n

Biosimilar entry timing: For biologics approaching the end of their 12-year exclusivity period, biosimilar developers can use FOIA requests \u2014 combined with the BPCIA patent dance data exchanged under the 351(k) process \u2014 to construct the most complete available picture of the reference biologic’s manufacturing and clinical data package. This is relevant for commercial launch planning because biosimilar developers who achieve interchangeability designation (which requires switching study data demonstrating no greater safety\/efficacy risk from multiple switches between the biosimilar and reference product) capture substantially higher market share than those without it.<\/p>\n\n\n\n

Drug repurposing due diligence: Abandoned IND data obtained via FOIA represents potential IP-free technical due diligence for drug repurposing initiatives. If the preclinical toxicology package for an abandoned oncology compound is available, and a new indication is identified where the compound’s mechanism is relevant, the FOIA-derived data can support a new IND filing without repeat animal studies \u2014 subject to FDA agreement on data bridging.<\/p>\n\n\n\n

FOIA Logs as a Market Signal<\/strong><\/h3>\n\n\n\n

The FDA publishes its FOIA request logs periodically, identifying the types of records requested (though not always the specific drugs). Industry practitioners have used these logs to track competitor FOIA activity patterns. A sudden increase in FOIA requests directed at a specific therapeutic area or drug class can signal competitive intelligence gathering activity \u2014 potentially predicting a competitor’s pipeline strategy or a forthcoming M&A move.<\/p>\n\n\n\n

For portfolio managers, monitoring FOIA request patterns in a therapeutic area can serve as a soft leading indicator of competitor interest in a specific mechanism, complementary to patent citation analysis and licensing deal tracking.<\/p>\n\n\n\n

Key Takeaways: Investment Strategy<\/strong><\/h3>\n\n\n\n

FOIA-derived IND data has specific, high-value use cases: mechanism-class risk profiling, biosimilar entry planning, and drug repurposing technical diligence. FDA FOIA log monitoring can function as a market intelligence signal for anticipating competitor moves. The intelligence value is highest for abandoned programs in active therapeutic areas where class effects from the predecessor compound remain relevant to the next-generation asset.<\/p>\n\n\n\n

\n\n\n\n

The Public Interest Argument: Drug Repurposing, Clinical Transparency, and Exemption 4 Pushback<\/strong><\/h2>\n\n\n\n

The Competing Values Tension<\/strong><\/h3>\n\n\n\n

The FDA’s current approach to IND confidentiality reflects a regulatory choice: protect sponsor commercial interests during the investigational phase to preserve R&D investment incentives, then increase transparency post-approval to support informed clinical practice. Critics of this approach, including Public Citizen and academic medical researchers, argue that it systematically withholds safety data that could inform treatment decisions in real time and forecloses drug repurposing opportunities that could benefit patients with conditions for which no approved therapy exists.<\/p>\n\n\n\n

The tension is not hypothetical. When a drug sponsor abandons an IND for a compound that showed Phase 1 tolerability in an oncology indication but failed on efficacy, the safety data package from that trial \u2014 which demonstrates what doses humans can tolerate, what PK behavior the compound exhibits, and what adverse events emerged \u2014 may be directly relevant to researchers investigating the same compound in a different indication. If that data remains inaccessible under Exemption 4, researchers must either repeat the Phase 1 work (at cost and at ethical exposure to trial participants) or forgo development.<\/p>\n\n\n\n

The Repurposing Argument in FOIA Requests<\/strong><\/h3>\n\n\n\n

A FOIA requester seeking abandoned IND data for repurposing purposes has a substantive public interest argument. The argument has several components: the drug is no longer commercially developed by the sponsor; the safety data from the original Phase 1 trial represents a completed human exposure dataset that is not replicated anywhere in the published literature; the absence of this data requires duplication of clinical risk to trial participants; and the only beneficiary of continued confidentiality is the sponsor, who no longer has an active program.<\/p>\n\n\n\n

Academic medical centers and non-profit research organizations \u2014 particularly those focused on neglected tropical diseases, rare pediatric conditions, or repurposing of generic compounds \u2014 are the parties most likely to succeed with this argument. The Ro 24-7429 precedent supports it. The labetalol litigation suggests the argument has limits when the sponsor has ongoing commercial interests in the relevant compound class.<\/p>\n\n\n\n

The Exemption 4 Pushback: AlliedSignal and Argus Leader in Tension<\/strong><\/h3>\n\n\n\n

Post-Argus Leader, the Supreme Court’s ‘customary privacy’ standard for Exemption 4 was intended to resolve the circuit split on the competitive harm requirement. But it created a new ambiguity: what does ‘customary’ mean for data that a pharmaceutical company is legally required to submit to the FDA as a condition of conducting clinical trials? The sponsor did not ‘voluntarily’ share the data in the way a company voluntarily submits a comment to a proposed rulemaking; the IND submission is a legal prerequisite. Some scholars have argued that compelled regulatory disclosures should not benefit from Exemption 4 in the same way that genuinely voluntary commercial disclosures do \u2014 a position that, if adopted by courts, would materially weaken the IND confidentiality framework.<\/p>\n\n\n\n

This argument has not prevailed in post-Argus Leader FOIA litigation involving the FDA, but it remains an active area of academic and advocacy debate. For practitioners making fee waiver or public interest arguments in IND FOIA requests, awareness of this legal fault line is relevant for structuring the appeal record.<\/p>\n\n\n\n

Key Takeaways: Public Interest Arguments<\/strong><\/h3>\n\n\n\n

The strongest public interest FOIA arguments for IND data combine program abandonment, patient access rationale (lack of alternative therapies), and a demonstrated absence of ongoing commercial sensitivity. The Argus Leader ‘customary privacy’ standard is legally stronger for sponsors than the pre-2019 National Parks test, but the argument that compelled regulatory submissions should receive less Exemption 4 protection than voluntary disclosures remains a viable litigation theory worth developing in appeal records.<\/p>\n\n\n\n

\n\n\n\n

FOIA Request Checklist and Decision Framework<\/strong><\/h2>\n\n\n\n

Pre-Filing Decision Matrix<\/strong><\/h3>\n\n\n\n

Before investing time and resources in a FOIA request targeting IND data, work through the following analytical sequence:<\/p>\n\n\n\n

Is the IND active or abandoned? If active and not publicly acknowledged, the probability of any disclosure is near zero. If abandoned or withdrawn, proceed.<\/p>\n\n\n\n

Has the compound received NDA\/BLA approval? If yes, the Drugs@FDA approval package and EMA clinical study reports (if applicable) likely contain what you need without any FOIA process.<\/p>\n\n\n\n

Is the data available in ClinicalTrials.gov results records, published Phase 1 literature, or investor\/conference presentations? If yes, no FOIA request is warranted.<\/p>\n\n\n\n

Is the requesting party’s purpose academic\/public health or commercial? Academic requesters with a fee waiver argument have a better probability of release and lower cost exposure. Commercial requesters face higher scrutiny and no fee waiver.<\/p>\n\n\n\n

Is the specific data type requested safety\/efficacy data or CMC\/manufacturing data? Safety and efficacy data from abandoned INDs is the highest-probability disclosure category. Manufacturing and synthesis data has near-zero probability of release under Exemption 4 regardless of program status.<\/p>\n\n\n\n

What is the estimated value of the data if obtained? If the value clearly exceeds litigation costs ($100K-$500K), litigation is a rational option after administrative denial. If not, administrative appeal only.<\/p>\n\n\n\n

FOIA Request Submission Checklist<\/strong><\/h3>\n\n\n\n

Identify the correct FDA center (CDER for small molecules and most biologics, CBER for vaccines, blood products, tissue-engineered products). Address the request to the appropriate FOIA office. Include the requester’s full name, mailing address, and telephone contact. Identify the drug by INN and IND number (if known). Specify document categories with precision (e.g., ‘pharmacology review documents,’ ‘IND annual reports,’ ‘expedited safety reports’ rather than ‘all IND documents’). State that the IND is believed to be abandoned and identify the basis for that belief (e.g., no ClinicalTrials.gov enrollment activity for more than two years, no company press releases regarding the program). Include a public interest fee waiver argument if applicable, citing the contributing-to-public-understanding standard. Specify a maximum fee cap. Submit electronically through accessdata.fda.gov\/scripts\/foi\/FOIRequest.<\/p>\n\n\n\n

Post-Submission Timeline Expectations<\/strong><\/h3>\n\n\n\n

Acknowledge receipt within 5-10 business days. Formal determination due at 20 working days (statutory) \u2014 in practice, expect 6-12 months for complex requests in 2025-2026. At 20 working days without response, the constructive denial appeal right activates. File administrative appeal within 90 days of any formal denial. Consider federal district court litigation after exhausting administrative remedies if the data value supports the investment.<\/p>\n\n\n\n

Key Takeaways: Decision Framework<\/strong><\/h3>\n\n\n\n

The FOIA pathway to IND data is narrow, time-intensive, and probabilistically weak for most request types. The highest-probability use case is a narrowly scoped request for safety\/efficacy data from a documented abandoned program, filed by a non-commercial requester with a public interest argument. For commercial competitive intelligence applications, the Drugs@FDA post-approval reviewer documents, EMA Policy 0070 clinical study reports, and ClinicalTrials.gov results records collectively represent a more productive, lower-cost intelligence pipeline than FOIA for IND data.<\/p>\n\n\n\n

\n\n\n\n

Disclosure Probability Reference Table<\/strong><\/h2>\n\n\n\n
IND Data Category<\/th>Program Status<\/th>Requesting Party<\/th>Probability of Disclosure<\/th>Key Controlling Factors<\/th><\/tr><\/thead>
FDA pharmacology review<\/td>Abandoned<\/td>Academic\/non-profit<\/td>Moderate<\/td>Public interest framing, no ongoing commercial sensitivity<\/td><\/tr>
IND annual reports<\/td>Abandoned<\/td>Academic\/non-profit<\/td>Moderate<\/td>Dependent on scope of public interest argument<\/td><\/tr>
Clinical protocols<\/td>Abandoned<\/td>Any<\/td>Low-Moderate<\/td>ClinicalTrials.gov may already have this; overlap with Exemption 4<\/td><\/tr>
IND safety reports (personal)<\/td>Active<\/td>Individual participant<\/td>High<\/td>Mandatory disclosure per 21 CFR \u00a7 312.130<\/td><\/tr>
CMC\/synthesis\/manufacturing data<\/td>Any<\/td>Any<\/td>Very Low<\/td>Core trade secret regardless of program status<\/td><\/tr>
IND existence confirmation<\/td>Active, undisclosed<\/td>Any<\/td>Near Zero<\/td>21 CFR \u00a7 312.130 no-acknowledgment rule<\/td><\/tr>
Safety\/efficacy data<\/td>Active, unapproved<\/td>Any<\/td>Very Low<\/td>Exemption 4 applies; no abandonment argument available<\/td><\/tr>
Post-NDA approval package<\/td>Approved<\/td>Any<\/td>High (no FOIA needed)<\/td>Drugs@FDA provides without request<\/td><\/tr>
Exception-from-informed-consent data<\/td>Active or closed<\/td>Any<\/td>Moderate<\/td>Specific Docket 95S-0158 FOIA pathway required<\/td><\/tr>
BLA clinical data (EU-approved)<\/td>Approved<\/td>Any<\/td>High (no FOIA needed)<\/td>EMA Policy 0070 clinical study reports<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n","protected":false},"excerpt":{"rendered":"

For IP teams, portfolio managers, competitive intelligence leads, and institutional investors who need to know what the FDA is holding […]<\/p>\n","protected":false},"author":1,"featured_media":34914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-10996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/10996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=10996"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/10996\/revisions"}],"predecessor-version":[{"id":38067,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/10996\/revisions\/38067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34914"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=10996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=10996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=10996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}